 | • レポートコード：MRC2301H080 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、224ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：バイオ |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の市場調査によると、2021年の169.7億ドルであった世界のがんバイオマーカー市場規模は、2022年には189.8億ドルへ達し、2027年までに年平均12.04%成長して335.8億ドルへ拡大すると予想されています。本調査資料では、がんバイオマーカーの世界市場を調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、生体分子種類別（エピジェネティック、遺伝的、代謝、プロテオミクス）分析、がん種類別（血液がん、乳がん、大腸がん、肺がん、その他）分析、技術別（バイオインフォマティクス、細胞遺伝学、画像技術、イムノアッセイ、OMICS技術）分析、用途別（診断、創薬・開発、予後、リスクアセスメント）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。また、当書ではAbbott Laboratories, Inc.、Agilent Technologies、Becton, Dickinson and Company、Bio-Rad Laboratories、Biomerieux、Danaher Corporation、F. Hoffmann-La Roche Ltd、GE Healthcare、Hologic、Illumina, Inc.、Merck & Co.、Myriad Genetics、Qiagen N.V.、Quest Diagnostics、Roche Diagnostics、Sysmex Corporation、Thermo Fisher Scientificなどの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概 ・市場インサイト ・世界のがんバイオマーカー市場規模：生体分子種類別 - エピジェネティック生体分子における市場規模 - 遺伝的生体分子における市場規模 - 代謝生体分子における市場規模 - プロテオミクス生体分子における市場規模 ・世界のがんバイオマーカー市場規模：がん種類別 - 血液がんにおける市場規模 - 乳がんにおける市場規模 - 大腸がんにおける市場規模 - 肺がんにおける市場規模 - その他がんにおける市場規模 ・世界のがんバイオマーカー市場規模：技術別 - バイオインフォマティクスにおける市場規模 - 細胞遺伝学における市場規模 - 画像技術における市場規模 - イムノアッセイにおける市場規模 - OMICS技術における市場規模 ・世界のがんバイオマーカー市場規模：用途別 - 診断における市場規模 - 創薬・開発における市場規模 - 予後における市場規模 - リスクアセスメントにおける市場規模 ・世界のがんバイオマーカー市場規模：地域別 - 南北アメリカのがんバイオマーカー市場規模 アメリカのがんバイオマーカー市場規模 カナダのがんバイオマーカー市場規模 ブラジルのがんバイオマーカー市場規模 ... - アジア太平洋のがんバイオマーカー市場規模 日本のがんバイオマーカー市場規模 中国のがんバイオマーカー市場規模 インドのがんバイオマーカー市場規模 韓国のがんバイオマーカー市場規模 台湾のがんバイオマーカー市場規模 ... - ヨーロッパ/中東/アフリカのがんバイオマーカー市場規模 イギリスのがんバイオマーカー市場規模 ドイツのがんバイオマーカー市場規模 フランスのがんバイオマーカー市場規模 ロシアのがんバイオマーカー市場規模 ... - その他地域のがんバイオマーカー市場規模 ・競争状況 ・企業情報 |
The Global Cancer Biomarkers Market size was estimated at USD 16.97 billion in 2021 and expected to reach USD 18.98 billion in 2022, and is projected to grow at a CAGR 12.04% to reach USD 33.58 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Cancer Biomarkers to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Biomolecule Type, the market was studied across Epigenetic, Genetic, Metabolic, and Proteomic.
Based on Cancer Type, the market was studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Skin Cancer, and Stomach Cancer.
Based on Technology, the market was studied across Bioinformatics, Cytogenetics, Imaging Technology, Immunoassays, and OMICS Technology.
Based on Application, the market was studied across Diagnostics, Drug Discovery and Development, Prognostics, and Risk Assessment.
Based on End User, the market was studied across Academic and Cancer Research Centers, Hospitals, and Speciality Centers.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Cancer Biomarkers market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Biomarkers Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Biomarkers Market, including Abbott Laboratories, Inc., Agilent Technologies, Becton, Dickinson and Company, Bio-Rad Laboratories, Biomerieux, Danaher Corporation, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic, Illumina, Inc., Merck & Co., Myriad Genetics, Qiagen N.V., Quest Diagnostics, Roche Diagnostics, Sysmex Corporation, and Thermo Fisher Scientific.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Cancer Biomarkers Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Biomarkers Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Biomarkers Market?
4. What is the competitive strategic window for opportunities in the Global Cancer Biomarkers Market?
5. What are the technology trends and regulatory frameworks in the Global Cancer Biomarkers Market?
6. What is the market share of the leading vendors in the Global Cancer Biomarkers Market?
7. What modes and strategic moves are considered suitable for entering the Global Cancer Biomarkers Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing instances of cancer globally and higher acceptance for treatment in developing economies
5.1.1.2. Paradigm Shift in Healthcare from Disease Diagnosis to Risk Assessment or Early Diagnosis
5.1.1.3. Technology advancement coupled with the research on cancer biomarkers
5.1.1.4. Increasing Use of Cancer Biomarkers in Drug Discovery and Development
5.1.2. Restraints
5.1.2.1. Unfavourable reimbursement policies and regulatory framework
5.1.2.2. Technical issues related to sample collection and storage
5.1.3. Opportunities
5.1.3.1. Growing demand for personalized medicines
5.1.3.2. Trend of the companion diagnostic for the safe and effective use of a corresponding drug or biological product
5.1.4. Challenges
5.1.4.1. High capital investment associated with low benefit ratio
5.2. Cumulative Impact of COVID-19
6. Cancer Biomarkers Market, by Biomolecule Type
6.1. Introduction
6.2. Epigenetic
6.3. Genetic
6.4. Metabolic
6.5. Proteomic
7. Cancer Biomarkers Market, by Cancer Type
7.1. Introduction
7.2. Blood Cancer
7.3. Breast Cancer
7.4. Colorectal Cancer
7.5. Lung Cancer
7.6. Ovarian Cancer
7.7. Prostate Cancer
7.8. Skin Cancer
7.9. Stomach Cancer
8. Cancer Biomarkers Market, by Technology
8.1. Introduction
8.2. Bioinformatics
8.3. Cytogenetics
8.4. Imaging Technology
8.5. Immunoassays
8.6. OMICS Technology
9. Cancer Biomarkers Market, by Application
9.1. Introduction
9.2. Diagnostics
9.3. Drug Discovery and Development
9.4. Prognostics
9.5. Risk Assessment
10. Cancer Biomarkers Market, by End User
10.1. Introduction
10.2. Academic and Cancer Research Centers
10.3. Hospitals
10.4. Speciality Centers
11. Americas Cancer Biomarkers Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Cancer Biomarkers Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Cancer Biomarkers Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Abbott Laboratories, Inc.
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Agilent Technologies
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Becton, Dickinson and Company
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Bio-Rad Laboratories
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Biomerieux
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Danaher Corporation
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. F. Hoffmann-La Roche Ltd
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. GE Healthcare
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Hologic
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Illumina, Inc.
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Merck & Co.
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Myriad Genetics
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Qiagen N.V.
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Quest Diagnostics
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Roche Diagnostics
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Sysmex Corporation
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Thermo Fisher Scientific
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing